Open Therapeutics to Exhibit at the American Society of Gene & Cell Therapy (ASGCT) Annual Conference, 15-19 May, 2022, Washington, DC.


Published on: May 18, 2022

Providing Information about the Open Therapeutics’ Therapoid Open Science Platform.

Cincinnati, OH — May 16th, 2022 — Open Therapeutics, an open science company, announces its Chair and interim CEO, Jason E. Barkeloo, will lead a the Open Therapeutics booth exhibit at the American Society of Gene & Cell Therapy (ASGCT) conference at the Walter E. Washington Convention Center, 801 Mt. Vernon Pl NW, Washington DC.

The Company is also proud to announce its advisor, Timothy Cripe, MD, PhD, will present Drug Modulation of the Myeloid Tumor Microenvironment to Enable Oncolytic HSV Immunotherapy, 850am, May 15th.

The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society’s members are scientists, physicians, patient advocates, and other professionals. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies.

The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT’s strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

Open Therapeutics’ mission is enabling the global research community to positively impact human, animal, plant, and global environmental health. is its free open science platform for the public, researchers, and students. It provides grant funding, free equipment, technologies, intellectual properties, forums, preprint server manuscript review tool, and ScienceCoins cryptocurrency awards.

As scientists and students collaborate within the free Therapoid scientific platform, they gain ScienceCoins awards. One might think of ScienceCoins as “Bitcoin for scientists.” For a limited time, when students and researchers freely register, they gain complimentary ScienceCoins*. According to Open Therapeutics founder, Jason E. Barkeloo, “I am proud to represent Open Therapeutics in its leadership of open science at this important conference. This is the first of many conferences we will present and advocate for the adoption of open science and our marquee platform, Therapoid.”

* The complimentary ScienceCoins awards are available for only a limited time and are open to any qualified registrant.

About Open Therapeutics

The Company freely provides the scientific community the Therapoid™ platform; an open science and open access collaboration ecosystem that puts scientists and students at the center of research for positively impacting human, animal, plant, and global environmental health. Therapoid freely provides intellectual properties (IP), copyrights, grant funding, free equipment, discussion forums, manuscript review tool, knowledge content center, career, and academic opportunities, ScienceCoins cryptocurrency awards, and non-fungible tokens (NFTs). All knowledge is freely provided under a comprehensively modified Creative Commons 4.0 ShareAlike (CC4.0 ShareAlike) license. The use of the Polygon layer 2 on the Ethereum blockchain has provided the Company with the opportunity to lead the development of DeSci dApps and develop Therapoid as a decentralized autonomous organization (DAO). Through creating the world’s biggest think tank, members who openly share can be seen by employment and student recruiters for career, job, and gig opportunities. Therapoid can be particularly beneficial to those in economically developing areas of Africa, Asia, and Latin America.

Media Contact:
Jason E. Barkeloo, Founder/Chair Open Therapeutics